





EFW

<div style="display: flex; justify-content: space-between; align-items: center;"> <div style="text-align: left;">  </div> <div> TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c)) </div> </div>					Docket No. 14185.6.1	
In Re Application Of: Holz et al.						
Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.	
10/786,240	02/25/2004	Not Assigned	022913	1614	2692	
Title: TYPE-1 METHOINYL AMINOPEPTIDASES INHIBITORS IN ANTIMICROBIAL TARGETING						
Address to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450						
37 CFR 1.97(b)						
1. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.						
37 CFR 1.97(c)						
2. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:						
<div style="margin-left: 40px;"> <input type="checkbox"/> the statement specified in 37 CFR 1.97(e); </div>						
OR						
<div style="margin-left: 40px;"> <input type="checkbox"/> the fee set forth in 37 CFR 1.17(p). </div>						

 TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))				Docket No. 14185.6.1	
Re Application: Holz et al.					
Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/786,240	02/25/2004	Not Assigned	022913	1614	2692
Title: TYPE-1 METHOINYL AMINOPEPTIDASES INHIBITORS IN ANTIMICROBIAL TARGETING					
Payment of Fee (Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))					
<input type="checkbox"/> A check in the amount of _____ is attached.					
<input checked="" type="checkbox"/> The Director is hereby authorized to charge and credit Deposit Account No. 23-3178 as described below.					
<input type="checkbox"/> Charge the amount of _____					
<input type="checkbox"/> Credit any overpayment.					
<input checked="" type="checkbox"/> Charge any additional fee required.					
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.					
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.					
Certificate of Transmission by Facsimile*			Certificate of Mailing by First Class Mail		
I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. _____)			I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on		
_____ (Date)			Nov. 19, 2004 (Date)		
_____ Signature			 Signature of Person Mailing Correspondence		
_____ Typed or Printed Name of Person Signing Certificate			John C. Stringham Typed or Printed Name of Person Mailing Certificate		
<p>*This certificate may only be used if paying by deposit account.</p> <div style="display: flex; justify-content: space-between;"> <div style="width: 45%;">  John C. Stringham, Reg. No. 40,831 WORKMAN NYDEGGER Phone: (801) 533-9800 </div> <div style="width: 45%; text-align: right;"> Dated: Nov. 19, 2004 </div> </div>					
CC:					



PATENT APPLICATION
Docket No: 14185.6.1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Holz et al.)	
)	
Appl. No.	10/786,240)	Art Unit
)	1614
Filed:	February 25, 2004)	
)	
Title:	TYPE-1 METHIONYL AMINOPEPTIDASES)	
	INHIBITORS IN ANTIMICROBIAL)	
	TARGETING)	
)	
Customer No.:	022,913)	

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR § 1.97

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Please find, pursuant to 37 C.F.R. § 1.98 (a) (1), enclosed Form PTO-1449 that contains a list of all patents, publications, or other items that have come to the attention of one or more of the individuals designated in 37 C.F.R. § 1.56 (c). While no representation is made that any of these references may be “prior art” within the meaning of that term under 37 C.F.R. §§ 102 or 103, the enclosed list of references is disclosed to fully comply with the duty of disclosure set forth in 37 C.F.R. § 1.56.

Pursuant to 37 C.F.R. § 1.97 (g) and (h), Applicant makes no representation that a search has been made or that the information cited is considered to be material to patentability. Additionally, Applicant makes no representation regarding the completeness of this list nor represents that other art does not exist.

Applicant has listed publication dates on the attached Form PTO-1449 based on information that is presently available to the undersigned attorney of record. The listed publication dates, however, should not be construed as an admission that the references were actually published on the dates indicated and Applicant reserves the right to establish that the actual publication dates of any of these references.

Appl. No. : 10/786,240
Filed : February 25, 2004

Applicant also reserves the right to establish patentability of the claimed invention over any of the listed references, and/or to prove that any of the listed references are not prior art, and/or to prove that any of the listed references do not enable or otherwise teach, suggest or disclose the claimed invention.

In accordance with 37 CFR §§ 1.97 and 1.98, a copy of each of the listed references or relevant portion thereof is enclosed.

In accordance with 37 C.F.R. § 1.98 (c), all English translations within the possession, custody, control or availability of anyone designated in 37 C.F.R. § 1.56 (c) of each non-English reference, if any, are also enclosed.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency or credit any overpayment to our Deposit Account No. 23-3178 in connection with filing this document and any other documents filed herewith.

DATED this 19 day of Nov. 2004.

Respectfully submitted,



JOHN C. STRINGHAM
Attorney for Applicant
Registration No. 40,831
Phone: (801) 533-9800

CUSTOMER NO.: 022,913

Applicant: Holz et al.

Serial No.: 10/786,240

Att'y Docket No.: 14476.32.1

Filing Date: February 25, 2004

For: TYPE-1 METHIONYL AMINOPEPTIDASES INHIBITORS IN
ANTIMICROBIAL TARGETINGINFORMATION DISCLOSURE CITATIONS MADE BY APPLICANTU.S. Patent Documents

Examiner Initial*	Document Number	Issue Date	Name
----------------------	--------------------	---------------	------

NONE

Foreign Patent Publications

Examiner Initial*	Document Number	Publication Date	Country or Patent Office
----------------------	--------------------	---------------------	-----------------------------

NONE

Other Documents

(including author, title, pertinent pages, etc.)

Examiner
Initial*

_____ A1	Copik et al., "Kinetic and Spectroscopic Characterization of the H178A Methionyl Aminopeptidases from <i>Escherichia coli</i> ." (2003) Biochemistry 42, 6283-6292.
_____ A2	D'souza et al., "Kinetic and Structural Characterization of Manganese(II)-Loaded Methionyl Aminopeptidases." (2002) Biochemistry 41, 13096-13105.
_____ A3	Lu Meng et al., "Overexpression and Divalent Metal Binding Properties of The Methionyl Aminopeptidase from <i>Pyrococcus furiosus</i> ." (2002) Biochemistry 41, 7199-7208.
_____ A4	Cosper et al., "Structural Evidence That the Methionyl Aminopeptidase from <i>Escherichia coli</i> Is a Mononuclear Metalloprotease." (2001) Biochemistry 40, 13302-13309.

Examiner:

Date Considered:

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609, draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant: Holz et al.
Serial No.: 10/786,240 Att'y Docket No.: 14476.32.1
Filing Date: February 25, 2004
For: TYPE-I METHIONYL AMINOPEPTIDASES INHIBITORS IN
ANTIMICROBIAL TARGETING

- _____ A5 D'souza et al, "Divalent Metal Binding Properties of the Methionyl Aminopeptidase from *Escherichia coli*." (2000) Biochemistry 39, 3817-3826.
- _____ A6 Lowther et al., Insights into the Mechanism of *E. Coli* Methionine Aminopeptidase from the Structural Analysis of Reaction Products and Phosphorous-Bases Transition State Analogs." (1999) Biochemistry 38, 14810-14819.
- _____ A7 D'souza et al., "The Methionyl Aminopeptidase from *Escherichia coli* Can Function as an Iron(II) Enzyme." (1999) Biochemistry 38, 11079-11085.

Examiner:

Date Considered:

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609, draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant: Holz et al.
Serial No.: 10/786,240 Att'y Docket No.: 14476.32.1
Filing Date: February 25, 2004
For: TYPE-1 METHIONYL AMINOPEPTIDASES INHIBITORS IN
ANTIMICROBIAL TARGETING

References Cited by Applicants

While the filing of Information Disclosure Statements is voluntary, the procedure is governed by the guidelines of Section 609 of the Manual of Patent Examining Procedure and 37 C.F.R. §§ 1.97 and 1.98. To be considered a proper Information Disclosure Statement, Form PTO-1449 shall be accompanied by a copy of each listed patent or publication or other item of information and a translation of the pertinent portions of foreign documents (if an existing translation is readily available to the applicant), an explanation of relevance of each reference not in the English language, and should be submitted in a timely manner as set out in MPEP Sec. 609.

Examiners will consider all citations submitted in conformance with 37 C.F.R. § 1.98 and MPEP Sec. 609 and place their initials adjacent the citations in the spaces provided on this form. Examiners will also initial citations not in conformance with the guidelines which may have been considered. A reference may be considered by the Examiner for any reason whether or not the citation is in full conformance with the guidelines. A line will be drawn through a citation if it is not in conformance with the guidelines AND has not been considered. A copy of the submitted form, as reviewed by the Examiner, will be returned to the applicant with the next communication. The original of the form will be entered into the application file.

Each citation initialed by the Examiner will be printed on the issued patent in the same manner as references cited by the Examiner on Form PTO-892.

The reference designations "A1," "A2," etc. (referring to Applicant's reference 1, Applicant's reference 2, etc.) will be used by the Examiner in the same manner as Examiner's reference designations "A," "B," "C," etc. on Office Action Form PTO-1142.

W:\14185\6.1\DFR0000007019V001.doc

Examiner:

Date Considered:

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609, draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
